Triple-negative breast cancer: a potential new treatment is now in sight.

A pivotal moment – and no time to lose

Associate Professor Chaffer and her team believe that seviteronel also has the potential to treat other cancer types with this androgen receptor biomarker.

You can help fast-track discoveries like this through to clinical trial and directly to the people who need them most. You could provide remarkable new options for patients with aggressive TNBC and other hard-to-treat cancers.